Using plasma proteomic pattern for diagnosis,...

Details Using plasma proteomic pattern for diagnosis,... Using plasma proteomic pattern for diagnosis,...

2005-04-20

2009-11-24

Harris, Alana M (Department: 1643)

Chemistry: analytical and immunological testing

Nuclear magnetic resonance, electron spin resonance or other...

C473S174000, C473S179000, C473S063000, C473S064000, C473S086000, C424S009100, C424S009200, C514S001000

Reexamination Certificate

active

07622306

ABSTRACT:
The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.

REFERENCES:
patent: 2004/0005634 (2004-01-01), Patz, Jr. et al.
patent: 2004/0029194 (2004-02-01), Parish et al.
Pusztai, Lajos et al. Pharmacoproteomic Analysis of Prechemotherapy and Postchemotherapy Plasma Samples from Patients Receiving Neoadjuvant or Adjuvant Chemotherapy for Breast Carcinoma, Cancer 100: 1814-1822, May 2004.
Nora-Athina Viniou et al. Ida-Flag plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1(+) acute myeloid leukemia. European Journal of Haematology 72(1): 58-60, Jan. 2004.
Cortes et al. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 97(5): 1234-41, published online Feb. 2003, Mar. 1, 2003.
Albitar et al., “Proteomic-based prediction of response to therapy in acute myeloid leukemia,”Blood, 102(11):608a, 2003.
Kovarova et al., “Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine,”Electrophoresis, 21(17):3757-3764, 2000.
Yeoh et al., “Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling,”Cancer Cell, 1(2):133-143, 2002.
Anderson and Anderson, “The human plasma proteome,”Molec. Cell. Proteom., 1(11):845-867, 2002.
Hanash et al., “Identification of a cellular polypeptide that distinguishes between acute lymphoblastic leukemia in infants and in older children,”Blood, 73(2):527-532, 1989.
Hanash et al., “Lineage-related polypeptide markers in acute lymphoblastic leukemia detected by two-dimensional gel electrophoresis,”Proc. Natl. Acad. Sci. USA, 83(3):807-811, 1986.
Petricon etal., “Use of proteomic patterns in serum to identify ovarian cancer”.The Lancet, 359:572-577, 2002.
Voss et al., “Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocyticleukemia,”Int. J. Cancer, 91(2):180-186, 2001.
Extermann et al., “Relationship between cleaved L-selectin levels and the outcome of acute myeloid leukemia,”Blood, 92(9):3115-3122, 1998.
Ferrajoli et al., “The clinical significance or tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia,”Blood, 100(4):1215-1219, 2002.
Hanenberg et al., “Expression of the CEA gene family members NCA-50/90 and NCA-160 (CD66) in childhood acute lymphoblastic leukemias (ALLs) and in cell lines of B-cell origin,”Leukemia, 8(12):2127-2133, 1994.
Hayes et al., “Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662,”Clin. Cancer Res., 7(9):2703-2711, 2001.
Ito et al., “Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome,”Leukemia, 16(2):165-169, 2002.
Niitsu et al., “Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma,”Blood, 94(10):3541-3550, 1999.
Poley et al., “Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma,”Anticancer Res., 17:3021-3024, 1997.
Verstovsek et al., “Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome,”Leukemia, 15(8):1165-1170, 2001.
Verstovsek et al., “Significance of angiogenin plasma concentrations in patients with acute myeloid leukemia and advanced myelodysplastic syndrome,”Br. J. Haematol., 114(2):290-295, 2001.
Wysocki et al., “Carcinoembryonic antigen, alphafetoprotein and alpha and beta subunits of human chorionic gonadotropin in plasma of children with acute leukemia,”Acta Paediatr. Hung., 28(2):119-125, 1987.
Yokose and Ogata, “Plasma soluble interleukin-2 receptors in patients with myelodysplastic syndromes,”Leuk. Lymphoma, 28:171-176, 1997.

Affiliated with

Also associated with

Rating

Using plasma proteomic pattern for diagnosis,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Using plasma proteomic pattern for diagnosis,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Using plasma proteomic pattern for diagnosis,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4090815